High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-01

Study Completion Date

2100-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau. Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, together with their donors, are systematically enrolled. The registry collects demographic, diagnostic, treatment, prognosis, and medical expense information, as well as biospecimens for future analyses. Historical data are incorporated, and prospective data collection is ongoing with long-term follow-up planned. The registry is designed as a sustainable research infrastructure to provide comprehensive data on disease incidence, treatment patterns, outcomes, and resource utilization in a high-altitude setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ALLO-SCT in Elderly Patients With Hematological Disease

NCT04386928

Hematologic Diseases Stem Cell Transplant Complications

COMPLETED

Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT： Cohort Study

NCT06386445

Stem Cell Transplant Complications Acute Graft Versus Host Disease Acute Kidney Injury +1 more

NOT_YET_RECRUITING

Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

NCT05335226

Acute Leukemia

UNKNOWN NA

Diagnosis of Lung Complication After Allo-HSCT by Multiple Parameter System Through BAL

NCT04051372

Bronchoalveolar Lavage Fluid Lung Infection

UNKNOWN

Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation

NCT03423706

CD19-chimeric Antigen Receptor T Cells Relapsed and/or Refractory Acute Lymphoblastic Leukemia the Haploidentical Hematopoietic Stem Cell Transplantation

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

HALO-SCT is a prospective observational patient registry established at Qinghai University Affiliated Hospital, the first HSCT center in the Qinghai-Tibet Plateau. The registry aims to systematically capture patient and donor characteristics, transplant-related procedures, treatment outcomes, and long-term follow-up data in a high-altitude environment. Biospecimens, including peripheral blood and bone marrow samples, are collected at baseline and follow-up time points for future multi-omics studies. All clinical decisions follow routine practice; no experimental interventions are mandated by the protocol. The registry is intended as a long-term infrastructure project, with continuous data collection and integration into national and international collaborative research efforts.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematopoietic Stem Cell Transplantation (HSCT) Acute Myeloid Leukemia (AML) Leukemias, Acute Myeloid Myeloid Leukemias, Acute Hemophilia Myelodysplastic Syndrome MDS Lymphoma Leukemia Aplastic Anemia Bleeding Disorders Bone Marrow Transplantation Multiple Myeloma Myeloma, Multiple Immune Reconstitution

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HSCT Patients and Donors

Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, and their related or unrelated stem cell donors. Participants are prospectively followed for clinical outcomes and biospecimen collection under real-world conditions.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients diagnosed with hematologic diseases who are admitted to the HSCT center of Qinghai University Affiliated Hospital on or after September 1, 2023.
2. Planned or actual hematopoietic stem cell transplantation (HSCT).
3. Provision of signed informed consent.

Exclusion Criteria

1. Inability to provide long-term follow-up data due to severe comorbidities or logistical reasons.
2. Substance abuse compromising adherence.
3. Any condition judged by investigators to jeopardize safety or compliance.

Eligible Sex

ALL

Accepts Healthy Volunteers

No